11204 related articles for article (PubMed ID: 10091790)
1. Thin cutaneous malignant melanomas (< or =1.5 mm): identification of risk factors indicative of progression.
Massi D; Franchi A; Borgognoni L; Reali UM; Santucci M
Cancer; 1999 Mar; 85(5):1067-76. PubMed ID: 10091790
[TBL] [Abstract][Full Text] [Related]
2. Thick cutaneous malignant melanoma: a reappraisal of prognostic factors.
Massi D; Borgognoni L; Franchi A; Martini L; Reali UM; Santucci M
Melanoma Res; 2000 Apr; 10(2):153-64. PubMed ID: 10803716
[TBL] [Abstract][Full Text] [Related]
3. Independent prognostic importance of vascular invasion in nodular melanomas.
Straume O; Akslen LA
Cancer; 1996 Sep; 78(6):1211-9. PubMed ID: 8826942
[TBL] [Abstract][Full Text] [Related]
4. Disease progression in patients with thin cutaneous melanomas (tumour thickness < or = 0.75 mm): clinical and epidemiological data from the Tumour Center Munich 1977-98.
Schmid-Wendtner MH; Baumert J; Eberle J; Plewig G; Volkenandt M; Sander CA
Br J Dermatol; 2003 Oct; 149(4):788-93. PubMed ID: 14616371
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.
Clemente CG; Mihm MC; Bufalino R; Zurrida S; Collini P; Cascinelli N
Cancer; 1996 Apr; 77(7):1303-10. PubMed ID: 8608507
[TBL] [Abstract][Full Text] [Related]
6. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors.
Monteagudo C; Martin JM; Jorda E; Llombart-Bosch A
J Clin Pathol; 2007 Jun; 60(6):596-9. PubMed ID: 16522748
[TBL] [Abstract][Full Text] [Related]
7. Prognosis of thick cutaneous melanoma.
Kim SH; Garcia C; Rodriguez J; Coit DG
J Am Coll Surg; 1999 Mar; 188(3):241-7. PubMed ID: 10065812
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological significance of intratumoral and peritumoral lymphocytes and lymphocyte score based on the histologic subtypes of cutaneous melanoma.
Park CK; Kim SK
Oncotarget; 2017 Feb; 8(9):14759-14769. PubMed ID: 28107203
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in young women with cutaneous melanoma.
Burton AL; Egger ME; Quillo AR; Stromberg AJ; Hagendoorn L; Scoggins CR; Martin RC; McMasters KM; Callender GG
Am J Surg; 2014 Jan; 207(1):102-8. PubMed ID: 24330977
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in thin cutaneous malignant melanoma.
Månsson-Brahme E; Carstensen J; Erhardt K; Lagerlöf B; Ringborg U; Rutqvist LE
Cancer; 1994 May; 73(9):2324-32. PubMed ID: 8168037
[TBL] [Abstract][Full Text] [Related]
11. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma.
Burton AL; Gilbert J; Farmer RW; Stromberg AJ; Hagendoorn L; Ross MI; Martin RC; McMasters KM; Scoggins CR; Callender GG
Am Surg; 2011 Aug; 77(8):1009-13. PubMed ID: 21944515
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
13. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas.
Massi D; Franchi A; Borgognoni L; Reali UM; Santucci M
Hum Pathol; 1999 Mar; 30(3):339-44. PubMed ID: 10088554
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous malignant melanoma in southern Sweden 1965, 1975, and 1985. Prognostic factors and histologic correlations.
Måsbäck A; Westerdahl J; Ingvar C; Olsson H; Jonsson N
Cancer; 1997 Jan; 79(2):275-83. PubMed ID: 9010101
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in 1,521 melanoma patients with distant metastases.
Barth A; Wanek LA; Morton DL
J Am Coll Surg; 1995 Sep; 181(3):193-201. PubMed ID: 7670677
[TBL] [Abstract][Full Text] [Related]
16. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods.
Balch CM; Murad TM; Soong SJ; Ingalls AL; Halpern NB; Maddox WA
Ann Surg; 1978 Dec; 188(6):732-42. PubMed ID: 736651
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic features and behavior of cutaneous eyelid melanoma.
Vaziri M; Buffam FV; Martinka M; Oryschak A; Dhaliwal H; White VA
Ophthalmology; 2002 May; 109(5):901-8. PubMed ID: 11986095
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients.
Donizy P; Zietek M; Halon A; Leskiewicz M; Kozyra C; Matkowski R
Diagn Pathol; 2015 Jul; 10():86. PubMed ID: 26134500
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic factors in thin cutaneous malignant melanoma].
Massi D; Franchi A; Santucci M
Pathologica; 2002 Dec; 94(6):282-9. PubMed ID: 12540991
[TBL] [Abstract][Full Text] [Related]
20. [Clinical course of cutaneous melanoma of the head and neck, and the factors affecting patient survival].
Tarkov SA; Mikhnin AE; Shelekhova KV; Frolova OS; Nefedov AO
Vopr Onkol; 2013; 59(1):114-7. PubMed ID: 23814837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
